[HTML][HTML] Loss of CHD1 promotes heterogeneous mechanisms of resistance to AR-targeted therapy via chromatin dysregulation
Metastatic prostate cancer is characterized by recurrent genomic copy number alterations
that are presumed to contribute to resistance to hormone therapy. We identified CHD1 loss …
that are presumed to contribute to resistance to hormone therapy. We identified CHD1 loss …
Discovery of ARD-1676 as a highly potent and orally efficacious AR PROTAC degrader with a broad activity against AR mutants for the treatment of AR+ human …
We report herein the discovery and extensive characterization of ARD-1676, a highly potent
and orally efficacious PROTAC degrader of the androgen receptor (AR). ARD-1676 was …
and orally efficacious PROTAC degrader of the androgen receptor (AR). ARD-1676 was …
[HTML][HTML] MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer
Neuroendocrine prostate cancer (NEPC) is an aggressive malignancy with no effective
targeted therapies. The oncogenic MUC1-C protein is overexpressed in castration-resistant …
targeted therapies. The oncogenic MUC1-C protein is overexpressed in castration-resistant …
[HTML][HTML] Resolving the immune landscape of human prostate at a single-cell level in health and cancer
The prostate gland produces prostatic fluid, high in zinc and citrate and essential for the
maintenance of spermatozoa. Prostate cancer is a common condition with limited treatment …
maintenance of spermatozoa. Prostate cancer is a common condition with limited treatment …
[HTML][HTML] Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapse
Prostate cancer is heterogeneous and patients would benefit from methods that stratify those
who are likely to respond to systemic therapy. Here, we employ single-cell assays for …
who are likely to respond to systemic therapy. Here, we employ single-cell assays for …
Emerging variants of castration-resistant prostate cancer
Metastatic castration-resistant prostate cancer (CRPC) is associated with substantial clinical,
pathologic, and molecular heterogeneity. Most tumors remain driven by androgen receptor …
pathologic, and molecular heterogeneity. Most tumors remain driven by androgen receptor …
[HTML][HTML] ARv7 represses tumor-suppressor genes in castration-resistant prostate cancer
L Cato, J de Tribolet-Hardy, I Lee, JT Rottenberg… - Cancer cell, 2019 - cell.com
Androgen deprivation therapy for prostate cancer (PCa) benefits patients with early disease,
but becomes ineffective as PCa progresses to a castration-resistant state (CRPC). Initially …
but becomes ineffective as PCa progresses to a castration-resistant state (CRPC). Initially …
Alternative splicing in prostate cancer
A Paschalis, A Sharp, JC Welti, A Neeb… - Nature reviews Clinical …, 2018 - nature.com
Androgen receptor (AR) splice variants (AR-Vs) have been implicated in the development
and progression of metastatic prostate cancer. AR-Vs are truncated isoforms of the AR, a …
and progression of metastatic prostate cancer. AR-Vs are truncated isoforms of the AR, a …
[HTML][HTML] MiR-205-driven downregulation of cholesterol biosynthesis through SQLE-inhibition identifies therapeutic vulnerability in aggressive prostate cancer
C Kalogirou, J Linxweiler, P Schmucker… - Nature …, 2021 - nature.com
Prostate cancer (PCa) shows strong dependence on the androgen receptor (AR) pathway.
Here, we show that squalene epoxidase (SQLE), an enzyme of the cholesterol biosynthesis …
Here, we show that squalene epoxidase (SQLE), an enzyme of the cholesterol biosynthesis …
Non-canonical functions of the RB protein in cancer
The canonical model of RB-mediated tumour suppression developed over the past 30 years
is based on the regulation of E2F transcription factors to restrict cell cycle progression …
is based on the regulation of E2F transcription factors to restrict cell cycle progression …